News

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

How artificial intelligence could enhance clinical trials.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Research from the iMIND lab at Duke University.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Retinal imaging and the future of early Alzheimer diagnosis.

New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Recapping a recent conversation led by Dilsher S. Dhoot, MD.

Patients express mixed feelings about AI in healthcare, favoring its use for documentation and administrative tasks while demanding transparency and safety standards.

Cell and gene therapies in development for unmet needs.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.

Patients are highly motivated to slow disease progression with GA drugs and healthy lifestyle.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.

Catch up on this week's highlights in retina.

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.

Insights on injection technique and the future potential of SCS treatments.

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.

Make the most of your practice and your retina conference participation.

Innovative assistive devices empower patients with central vision loss to regain independence and enhance daily activities, transforming their quality of life.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).

Catch up on this week's highlights in retina.